The oncogenic role of GASC1 in chemically induced mouse skin cancer

Mammalian Genome

Volumn 26, Issue 11-12, 2015, Pages 591-597

  Ozaki, Yumi ^a   Fujiwara, Kyoko ^a   Ikeda, Maki ^a   Ozaki, Toshinori ^b   Terui, Tadashi ^a   Soma, Masayoshi ^a   Inazawa, Johji ^c   Nagase, Hiroki ^b  

^a NIHON UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b CHIBA CANCER CENTER   (Japan)

^c TOKYO MEDICAL AND DENTAL UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

GENE AMPLIFIED IN SQUAMOUS CELL CARCINOMA 1; HISTONE DEMETHYLASE; UNCLASSIFIED DRUG; 7,12 DIMETHYLBENZ[A]ANTHRACENE; JMJD2C PROTEIN, MOUSE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER INCIDENCE; CANCER SIZE; CANCER STAGING; CELL VIABILITY; CONTROLLED STUDY; GENE EXPRESSION; IN VITRO STUDY; MOUSE; NONHUMAN; SKIN CANCER; SKIN CARCINOGENESIS; UPREGULATION; ANIMAL; C57BL MOUSE; CARCINOGENESIS; CELL SURVIVAL; CHEMICALLY INDUCED; FEMALE; GENETIC ASSOCIATION STUDY; GENETIC PREDISPOSITION; GENETICS; KNOCKOUT MOUSE; MALE; METABOLISM; ONCOGENE; PAPILLOMA; PATHOLOGY; SKIN TUMOR; TUMOR CELL LINE; TUMOR VOLUME;

9,10-DIMETHYL-1,2-BENZANTHRACENE; ANIMALS; CARCINOGENESIS; CELL LINE, TUMOR; CELL SURVIVAL; FEMALE; GENETIC ASSOCIATION STUDIES; GENETIC PREDISPOSITION TO DISEASE; JUMONJI DOMAIN-CONTAINING HISTONE DEMETHYLASES; MALE; MICE, INBRED C57BL; MICE, KNOCKOUT; ONCOGENES; PAPILLOMA; SKIN NEOPLASMS; TUMOR BURDEN;

EID: 84947870725     PISSN: 09388990     EISSN: 14321777     Source Type: Journal    
DOI: 10.1007/s00335-015-9592-9     Document Type: Article

References (30)

1. Aasland R, Gibson TJ, Stewart AF (1995) The PHD finger: implications for chromatin-mediated transcriptional regulation. Trends Biochem Sci 20:56–59
2. Barski A, Cuddapah S, Cui K, Roh TY, Schones DE, Wang Z, Wei G, Chepelev I, Zhao K (2007) High-resolution profiling of histone methylations in the human genome. Cell 129:823–837
3. Berry WL, Janknecht R (2013) KDM4/JMJD2 histone demethylases: epigenetic regulators in cancer cells. Cancer Res 73:2936–2942
4. Black JC, Whetstine JR (2011) Chromatin landscape: methylation beyond transcription. Epigenetics 6:9–15
5. Bremner R, Balmain A (1990) Genetic changes in skin tumor progression: correlation between presence of a mutant ras gene and loss of heterozygosity on mouse chromosome 7. Cell 61:407–417
6. Cloos PA, Christensen J, Agger K, Maiolica A, Rappsilber J, Antal T, Hansen KH, Helin K (2006) The putative oncogene GASC1 demethylates tri- and di-methylated lysine 9 on histone H3. Nature 442:307–311
7. Dawson MA, Kouzarides T (2012) Cancer epigenetics: from mechanism to therapy. Cell 150:12–27
8. Ehrbrecht A, Muller U, Wolter M, Hoischen A, Koch A, Radlwimmer B, Actor B, Mincheva A, Pietsch T, Lichter P, Reifenberger G, Weber RG (2006) Comprehensive genomic analysis of desmoplastic medulloblastomas: identification of novel amplified genes and separate evaluation of the different histological components. J Pathol 208:554–563
9. Fujiwara K, Ghosh S, Liang P, Morien E, Soma M, Nagase H (2015) Genome-wide screening of aberrant DNA methylation which associated with gene expression in mouse skin cancers. Mol Carcinog 54:178–188
10. Han W, Jung EM, Cho J, Lee JW, Hwang KT, Yang SJ, Kang JJ, Bae JY, Jeon YK, Park IA, Nicolau M, Jeffrey SS, Noh DY (2008) DNA copy number alterations and expression of relevant genes in triple-negative breast cancer. Genes Chromosom Cancer 47:490–499
11. Herman JG, Latif F, Weng Y, Lerman MI, Zbar B, Liu S, Samid D, Duan DS, Gnarra JR, Linehan WM (1994) Silencing of the VHL tumor-suppressor gene by DNA methylation in renal carcinoma. Proc Natl Acad Sci USA 91:9700–9704
12. Italiano A, Attias R, Aurias A, Perot G, Burel-Vandenbos F, Otto J, Venissac N, Pedeutour F (2006) Molecular cytogenetic characterization of a metastatic lung sarcomatoid carcinoma: 9p23 neocentromere and 9p23–p24 amplification including JAK2 and JMJD2C. Cancer Genet Cytogenet 167:122–130
13. Kang C, Song JJ, Lee J, Kim MY (2014) Epigenetics: an emerging player in gastric cancer. World J Gastroenterol 20:6433–6447
14. Kouskouti A, Talianidis I (2005) Histone modifications defining active genes persist after transcriptional and mitotic inactivation. EMBO J 24:347–357
15. Li F, Mao G, Tong D, Huang J, Gu L, Yang W, Li GM (2013) The histone mark H3K36me3 regulates human DNA mismatch repair through its interaction with MutSalpha. Cell 153:590–600
16. Liu G, Bollig-Fischer A, Kreike B, van de Vijver MJ, Abrams J, Ethier SP, Yang ZQ (2009) Genomic amplification and oncogenic properties of the GASC1 histone demethylase gene in breast cancer. Oncogene 28:4491–4500
17. Luo W, Chang R, Zhong J, Pandey A, Semenza GL (2012) Histone demethylase JMJD2C is a coactivator for hypoxia-inducible factor 1 that is required for breast cancer progression. Proc Natl Acad Sci USA 109:E3367–E3376
18. Quintanilla M, Haddow S, Jonas D, Jaffe D, Bowden GT, Balmain A (1991) Comparison of ras activation during epidermal carcinogenesis in vitro and in vivo. Carcinogenesis 12:1875–1881
19. Rodriguez-Paredes M, Esteller M (2011) Cancer epigenetics reaches mainstream oncology. Nat Med 17:330–339
20. Rui L, Emre NC, Kruhlak MJ, Chung HJ, Steidl C, Slack G, Wright GW, Lenz G, Ngo VN, Shaffer AL, Xu W, Zhao H, Yang Y, Lamy L, Davis RE, Xiao W, Powell J, Maloney D, Thomas CJ, Moller P, Rosenwald A, Ott G, Muller-Hermelink HK, Savage K, Connors JM, Rimsza LM, Campo E, Jaffe ES, Delabie J, Smeland EB, Weisenburger DD, Chan WC, Gascoyne RD, Levens D, Staudt LM (2010) Cooperative epigenetic modulation by cancer amplicon genes. Cancer Cell 18:590–605
21. Shilatifard A (2008) Molecular implementation and physiological roles for histone H3 lysine 4 (H3K4) methylation. Curr Opin Cell Biol 20:341–348
22. Shin S, Janknecht R (2007) Diversity within the JMJD2 histone demethylase family. Biochem Biophys Res Commun 353:973–977
23. Sun LL, Holowatyj A, Xu XE, Wu JY, Wu ZY, Shen JH, Wang SH, Li EM, Yang ZQ, Xu LY (2013) Histone demethylase GASC1, a potential prognostic and predictive marker in esophageal squamous cell carcinoma. Am J Cancer Res 3:509–517
24. Trojer P, Zhang J, Yonezawa M, Schmidt A, Zheng H, Jenuwein T, Reinberg D (2009) Dynamic histone H1 isotype 4 methylation and demethylation by histone Lysine methyltransferase G9a/KMT1C and the Jumonji domain-containing JMJD2/KDM4 proteins. J Biol Chem 284:8395–8405
25. Uimonen K, Merikallio H, Paakko P, Harju T, Mannermaa A, Palvimo J, Kosma VM, Soini Y (2014) GASC1 expression in lung carcinoma is associated with smoking and prognosis of squamous cell carcinoma. Histol Histopathol 29:797–804
26. Venturini L, You J, Stadler M, Galien R, Lallemand V, Koken MH, Mattei MG, Ganser A, Chambon P, Losson R, de TH (1999) TIF1gamma, a novel member of the transcriptional intermediary factor 1 family. Oncogene 18:1209–1217
27. Whetstine JR, Nottke A, Lan F, Huarte M, Smolikov S, Chen Z, Spooner E, Li E, Zhang G, Colaiacovo M, Shi Y (2006) Reversal of histone lysine trimethylation by the JMJD2 family of histone demethylases. Cell 125:467–481
28. Yang ZQ, Imoto I, Pimkhaokham A, Shimada Y, Sasaki K, Oka M, Inazawa J (2001) A novel amplicon at 9p23–24 in squamous cell carcinoma of the esophagus that lies proximal to GASC1 and harbors NFIB. Jpn J Cancer Res 92:423–428
29. You JS, Jones PA (2012) Cancer genetics and epigenetics: two sides of the same coin? Cancer Cell 22:9–20
30. Zentner GE, Henikoff S (2013) Regulation of nucleosome dynamics by histone modifications. Nat Struct Mol Biol 20:259–266